Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 154 publications
Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.
Journal: JAMA neurology
Published: August 10, 2026
Author's response to comment on "Variations in clinical features and disease burden of myasthenia gravis between racial and ethnic groups: A retrospective cohort study of two national databases".
Journal: Journal of the neurological sciences
Published: June 05, 2026
Failure of early B cell tolerance and possible BCR signaling dysregulation underlie NF155-mediated autoimmune nodopathies.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 20, 2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 23, 2025
Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 21, 2025
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study.
Journal: European journal of neurology
Published: October 15, 2025
B Cell Tolerance and BCR Signaling Dysregulation in NF155-Mediated Autoimmune Nodopathies.
Journal: bioRxiv : the preprint server for biology
Published: August 20, 2025
AChR Autoantibody Pathogenic Properties Are Heterogeneously Distributed and Undergo Temporal Changes Among Patients With Myasthenia Gravis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: July 18, 2025
Contribution of cellular immune dysregulation to myasthenia gravis pathology.
Journal: International review of neurobiology
Published: July 17, 2025
Variations in clinical features and disease burden of myasthenia gravis between racial and ethnic groups: A retrospective cohort study of two national databases.
Journal: Journal of the neurological sciences
Published: June 05, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
Journal: The New England journal of medicine
Published: April 09, 2025
Last Updated: 09/26/2026